Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).
Sasaki K, Nomura M, Kato K, Sakanaka K, Ito Y, Kadota T, Machida R, Kataoka T, Minashi K, Tsubosa Y, Kajiwara T, Fukuda H, Takeuchi H, Mizowaki T, Nishimura Y, Kitagawa Y. Sasaki K, et al. Jpn J Clin Oncol. 2024 Jan 7;54(1):103-107. doi: 10.1093/jjco/hyad137. Jpn J Clin Oncol. 2024. PMID: 37801434 Clinical Trial.
A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).
Shimomura A, Tamura K, Tanaka K, Mizutani T, Sasaki K, Sekino Y, Sawaki M, Shien T, Shibata T, Iwata H. Shimomura A, et al. Among authors: sasaki k. Jpn J Clin Oncol. 2021 Aug 30;51(9):1471-1474. doi: 10.1093/jjco/hyab101. Jpn J Clin Oncol. 2021. PMID: 34215870 Clinical Trial.
Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).
Shimomura A, Tamura K, Tanaka K, Mizutani T, Sasaki K, Sekino Y, Sawaki M, Shien T, Shibata T, Iwata H. Shimomura A, et al. Among authors: sasaki k. Jpn J Clin Oncol. 2021 Aug 30;51(9):1479. doi: 10.1093/jjco/hyab124. Jpn J Clin Oncol. 2021. PMID: 34296283 No abstract available.
A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, Mizusawa J, Sekino Y, Ono T, Aoyama H, Satomi K, Ichimura K, Kinoshita M, Ohno M, Ito Y, Nishikawa R, Fukuda H, Nishimura Y, Narita Y; Brain Tumor Study Group and Radiation Therapy Study Group of the Japan Clinical Oncology Group. Arakawa Y, et al. Among authors: sasaki k. BMC Cancer. 2021 Oct 15;21(1):1105. doi: 10.1186/s12885-021-08834-0. BMC Cancer. 2021. PMID: 34654402 Free PMC article. Clinical Trial.
Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.
Mitani S, Kato K, Daiko H, Ito Y, Nozaki I, Kojima T, Yano M, Nakagawa S, Ueno M, Watanabe M, Tsunoda S, Abe T, Kadowaki S, Kadota T, Sasaki K, Machida R, Kitagawa Y. Mitani S, et al. Among authors: sasaki k. J Gastroenterol. 2022 Jul;57(7):455-463. doi: 10.1007/s00535-022-01870-y. Epub 2022 May 11. J Gastroenterol. 2022. PMID: 35546373 Free PMC article.
Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
Hashimoto T, Tsukamoto S, Murofushi K, Ito Y, Hirano H, Tsukada Y, Sasaki K, Mizusawa J, Fukuda H, Takashima A, Kanemitsu Y. Hashimoto T, et al. Among authors: sasaki k. BJS Open. 2023 Nov 1;7(6):zrad110. doi: 10.1093/bjsopen/zrad110. BJS Open. 2023. PMID: 37931233 Free PMC article.
Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
Imamura Y, Kiyota N, Tahara M, Kodaira T, Hayashi R, Nishino H, Asada Y, Mitani H, Iwae S, Nishio N, Onozawa Y, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Kitabayashi R, Sasaki K, Homma A; Head, Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Imamura Y, et al. Among authors: sasaki k. Oral Oncol. 2024 May 30;154:106868. doi: 10.1016/j.oraloncology.2024.106868. Online ahead of print. Oral Oncol. 2024. PMID: 38820889
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Imaoka H, et al. Among authors: sasaki k. Jpn J Clin Oncol. 2024 Jun 7:hyae048. doi: 10.1093/jjco/hyae048. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38843879
6,641 results